NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

REGENERON PHARMACEUTICALS, INC.,
Appellant

v.

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., SAMSUNG BIOEPIS CO., LTD.,
Appellees

2024-1564, 2024-1567

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2022-01225, IPR2022-01226, IPR2023-00532, IPR2023-00533, and IPR2023-00566.

ON MOTION

O R D E R

Upon consideration of Regeneron Pharmaceuticals, Inc.'s unopposed motion to voluntarily dismiss the above-captioned appeals pursuant to Federal Rule of Appellate Procedure 42,

IT IS ORDERED THAT:

(1) The motion is granted, and the appeals are dismissed.

(2) Each party shall bear its own costs for each appeal.

FOR THE COURT

Jarrett B. Perlow
Clerk of Court

August 20, 2024
Date

ISSUED AS A MANDATE: August 20, 2024